Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall survival (OS) in Del19 patients. Preplanned analyses in Japanese patients from LUX‐Lung 3 were performed. Patients were random...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2015-09, Vol.106 (9), p.1202-1211
Main Authors: Kato, Terufumi, Yoshioka, Hiroshige, Okamoto, Isamu, Yokoyama, Akira, Hida, Toyoaki, Seto, Takashi, Kiura, Katsuyuki, Massey, Dan, Seki, Yoko, Yamamoto, Nobuyuki
Format: Article
Language:English
Subjects:
Acne
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma of Lung
Adult
Afatinib
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Appetite loss
Asian People - genetics
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Confidence intervals
Diarrhea
Disease control
Disease-Free Survival
Drug dosages
Epidermal growth factor
epidermal growth factor receptor
Epidermal growth factor receptors
ErbB Receptors - genetics
Female
Humans
Japanese
Leukopenia
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Male
Middle Aged
Mutation
Mutation - genetics
Nausea
Neutropenia
non‐small cell lung cancer
Original
Patients
Pemetrexed - administration & dosage
Pharmaceuticals
Quinazolines - therapeutic use
Research funding
Stomatitis
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall survival (OS) in Del19 patients. Preplanned analyses in Japanese patients from LUX‐Lung 3 were performed. Patients were randomized 2:1 to afatinib or cisplatin/pemetrexed, stratified by mutation type (Del19/L858R/Other). Primary endpoint was PFS (independent review). Secondary endpoints included OS, objective response, and safety. Median PFS (data cut‐off: February 2012) for afatinib versus cisplatin/pemetrexed was 13.8 vs 6.9 months (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.20–0.70; P = 0.0014) in all Japanese patients (N = 83), with more pronounced improvements in those with common mutations (Del19/L858R; HR, 0.28; 95% CI, 0.15–0.52; P 
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.12723